Bicyclic DGK Inhibitors for Selective T Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds that can inhibit diacylglycerol kinases (DGKα and DGKζ) to enhance T cell activation and overcome immune checkpoint suppression in treating proliferative disorders like cancer and viral infections, while maintaining selectivity over other kinases and ensuring safety and efficacy.
Innovation Solution
Development of tertiary amine substituted bicyclic compounds that act as inhibitors of DGKα and/or DGKζ, offering selectivity and stability, with potential use in pharmaceutical compositions for treating proliferative disorders and viral infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are developed to inhibit DGKα and DGKζ to enhance T cell activation, then T cell activation and anti-tumor immunity are improved, but selectivity over other kinases and lipid kinases must be maintained to avoid off-target effects
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (tertiary amine substituted bicyclic structures with particular substituent patterns) that confer selective binding to DGKα and DGKζ active sites while avoiding interaction with other kinase families. The compounds incorporate specific functional groups and stereochemical configurations that match the unique structural characteristics of DGK enzymes, enabling selective inhibition without affecting other kinases.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types, ring structures, and stereochemistry to optimize the balance between potency and selectivity. By adjusting these molecular parameters, the compounds achieve high affinity for DGKα/ζ while maintaining adequate selectivity margins against other kinases, resolving the contradiction between efficacy and safety.
2Reliability
If compounds are designed for high potency against DGKα and DGKζ, then therapeutic efficacy is improved, but drugability properties such as stability and bioavailability must also be ensured
Solution Approach 1:
The patent applies parameter changes by optimizing molecular parameters including molecular weight, lipophilicity, hydrogen bonding capacity, and metabolic stability to ensure compounds meet drugability criteria while maintaining high potency. The structural modifications balance pharmacological activity with pharmacokinetic properties, resolving the contradiction between efficacy and drugability.
3Reliability
If existing immunotherapy approaches using checkpoint inhibitors are used, then immune response is enhanced, but tumors may exploit multiple mechanisms including dysfunctional T-cell signaling and suppressive regulatory cells to evade immunity
Solution Approach 1:
The patent applies the intermediary principle by using DGK inhibitors as mediators to restore T cell signaling function. The compounds act as chemical intermediaries that correct the dysfunctional T-cell signaling pathway by blocking the negative regulatory effect of DGK enzymes, thereby enhancing T cell activation and overcoming tumor-induced immune suppression without directly targeting the tumor cells themselves.
Data Source
AI summary
Disclosed are compounds of Formula (I): or a salt thereof, wherein: X, Y, R1, R2, R4, R5, and R6 are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.